论文部分内容阅读
目的 观察瑞舒伐他汀片治疗急性心肌梗死的临床疗效和安全性.方法 将126例急性心肌梗死病患者随机分为对照组63例和试验组63例.对照组予以口服瑞舒伐他汀10 mg,qn;试验组予以口服瑞舒伐他汀20 mg,qn,2组均治疗1个月.比较2组患者的临床疗效、血清心肌肌钙蛋白T(cTnT)、同型半胱氨酸(Hcy)、胱抑素C(Cys C)、可溶性CD40L(sCD40L)水平,以及药物不良反应的发生情况.结果 治疗后,试验组和对照组的总有效率分别为95.24％(60例/63例)和84.13％(53例/63例),差异有统计学意义(P＜0.05).治疗后,试验组和对照组的cTnT分别为(2.14±0.38),(4.83±0.75)μg·L-1,Hcy分别为(13.21 ±2.07),(16.32±2.64)μmol·L-1,Cys-C分别为(0.58±0.08),(1.11±0.17)mg·L-1,sCD40L分别为(3.06±0.57),(4.26±0.71)μg·L-1,差异均有统计学意义(均P＜0.05).试验组的药物不良反应为再发心肌梗死,对照组的药物不良反应为再发心肌梗死和再次血运重建,试验组和对照组的总药物不良反应发生率分别为3.17％和6.35％,差异无统计学意义(P＞0.05).结论 瑞舒伐他汀片治疗急性心肌梗死可改善患者心功能,同时可降低血清cTnT、Hcy、Cys-C和sCD40L水平,且高剂量瑞舒伐他汀的临床疗效更好,安全性较高.“,”Objective To study the clinical efficacy and safety profile of high doses of rosuvastatin tablets in the treatment of acute myocardial infarction.Methods A total of 126 patients with acute myocardial infarction were randomly divided into the control group (n =63) and the treatment group (n =63).The control group received oral administration of 10 mg resuvastatin once daily at night time.The treatment group was given oral administration of 20 mg resuvastatin once daily at night time.Both groups were treated for 1 month.The clinical efficacy,serum cardiac troponin T(cTnT),homocysteine (Hcy),cystatin C (Cys-C),soluble CD40 ligand (sCD40L) level,and adverse drug reactions were compared between the two groups.Results After treatment,the total effective rate of the treatment group and control group were 95.24％ (60 cases/63 cases) and 84.13％ (53 cases/63 cases),respectively,and the difference was statistically significant (P ＜ 0.05).After treatment,there were significant differences between the treatment group and the control group in the level of cTnT [(2.14 ± 0.38) μg · L-1 vs (4.83±0.75) μg · L-1],Hcy [(13.21 ±2.07) μmol · L-1 vs (16.32±2.64) μmol · L-1],Cys-C [(0.58±0.08) mg · L-1 vs (1.11 ±0.17) mg· L-1] and sCD40L [(3.06 + 0.57) μg· L-1 vs (4.26 ±0.71) μg· L-1](allP＜0.05).The adverse drug reaction in the treatment group was recurrent myocardial infarction,and the adverse drug reactions in the control group were recurrent myocardial infarction and revascularization.The incidences of adverse drug reactions in treatment group and the control group were 3.17％ and 6.35％,respectively,with no significant difference (P ＞ 0.05).Conclusion Rosuvastatin,especially high-dose rosuvastatin,exerted high clinical efficacy in patients with acute myocardial infarction via improving heart function and reducing the level of serum cTnT,Hcy,Cys-C and sCD40L,while providing good safety profile.